374 results
Pharmacy Week is a time to recognize contributions that pharmacists and pharmacy technicians make in patient care. Hear how pharmacists contribute to expanded access of medications, helping to provide treatment to patients who need it.
The recommended adult immunization schedule for the United States, 2024, has been published in the Annals of Internal Medicine. Read about this resource, and other immunization resources offered by Annals.
DynaMedex makes the grade in a new study evaluating this point-of-care (POC) resource to answer real-world disease-related clinical questions.
In the final installment of this four-part series on statins for primary prevention of cardiovascular disease, we reflect on what we’ve learned throughout the series and distill it into simple, actionable takeaways.
Oral phenylephrine, common in many OTC cold medicines, is no longer generally recognized as an effective nasal decongestant due to growing body of evidence.
Many Primary Care physicians manage veterans because most veterans do not seek healthcare from Veterans Affairs (VA) services. Hear from Army veteran and DynaMed Deputy Editor Dr. Dan Randall about considerations for the care of veterans.
EBSCO Nursing Consultant Kate ONeill, DNP, RN, explores the global diabetes epidemic, the pivotal role of health care professionals in diabetes management, the power of education and technology in raising awareness of this pervasive health challenge.
Dynamic Health Editor-in-Chief Diane Hanson, RN, BSN, MM, FNAP, shares insights on leadership from her recent appearance on MissingLogic's "The TRU Leader" podcast. Read about the interview and check out the episode.
Every few months, another drug for potential use in treating dermatologic disorders seems to enter the pipeline. Patient choice is great, but unknown comparative efficacy, conflicts of interest, and prohibitive costs complicate this choice.
It’s not magic, but the magnitude of benefit for psilocybin compared to other available treatments for major depressive disorder plus its relative lack of adverse effects suggests that this treatment might be about ready for prime time.